Market Overview - The S&P 500 has lost positive momentum since the start of the year after a strong three-year performance, influenced by concerns over the AI market's long-term revenue potential, economic uncertainty, interest rate cuts, and geopolitical tensions such as the war in Iran [1] Defensive Stocks Recommendation - It is suggested to add defensive stocks to portfolios, particularly in the healthcare sector, as these companies tend to perform well even in challenging economic conditions [2] Company Analysis: Abbott Laboratories - Abbott Laboratories is favored due to its diversified healthcare business, which includes medical devices, diagnostics, nutrition, and established pharmaceuticals, allowing it to mitigate risks from any single segment [3] - The company's essential products make its revenue less susceptible to economic fluctuations [4] - Abbott has a market capitalization of $183 billion, a gross margin of 52.72%, and a dividend yield of 2.28%, having increased its dividend payments for over 50 consecutive years, indicating strong financial health and commitment to shareholder returns [5][6] Company Analysis: Intuitive Surgical - Intuitive Surgical is recognized as the global leader in robotic surgery, particularly with its Da Vinci surgical robots, which have contributed to consistent earnings growth [7] - The company benefits from a strong competitive advantage, as most surgeons are trained on Da Vinci systems, leading to a preference for these devices in surgical settings [9] - Intuitive Surgical has a market capitalization of $170 billion, a gross margin of 65.98%, and generates recurring revenue through the sale of accessories and instruments needed for surgeries, making it a resilient stock during market downturns [10]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the firm directly [3][6]. - The deadline to move the Court to serve as lead plaintiff is April 7, 2026, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [5]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval, leading to overstated regulatory and commercial prospects [5].

Core Viewpoint - Eli Lilly has experienced a decline in share price since reaching a $1 trillion market valuation, with concerns about its valuation and potential competition in the weight management market [1] Group 1: Market Position and Competition - Eli Lilly maintains a strong lead in the anti-obesity market, with new product launches expected to solidify its position and expand its market reach [2] - The company is preparing to launch orforglipron, an oral GLP-1 candidate, which could attract new patients who prefer oral therapies over subcutaneous options [2] - Orforglipron has shown strong clinical trial performance, positioning it as a potential best-in-class medicine in diabetes and obesity treatment [3] Group 2: Product Pipeline and Revenue Sources - Eli Lilly is targeting patients with high body mass indexes with retatrutide, which has demonstrated a remarkable 28.7% mean weight loss in a phase 3 study [3][4] - The company has a diverse portfolio beyond weight management, including billion-dollar drugs like Verzenio, which generated $5.7 billion in sales last year, and Taltz, which grew sales by 9% to $3.6 billion [6][7] - Eli Lilly's aggressive expansion into various therapeutic areas, including pain management, oncology, and immunology, supports its revenue growth strategy [7] Group 3: Valuation and Growth Potential - Eli Lilly trades at a forward earnings multiple of 27x, significantly higher than the healthcare sector average of 17.1x, reflecting its faster revenue and earnings growth compared to peers [8] - The company's deep pipeline of candidates is expected to drive growth in the medium term, making the stock attractive despite its premium valuation [8]

Core Thesis - Abbott Laboratories (ABT) is viewed positively due to its diversified healthcare model, strong market position in medical devices, and consistent dividend growth, despite facing near-term challenges [1][6]. Company Overview - Abbott Laboratories is a global healthcare company involved in medical devices, diagnostics, nutrition, and established pharmaceuticals, with nearly 70% of its revenue coming from medical devices and diagnostics [3]. - Key products include the FreeStyle Libre glucose monitor and heart repair devices, which contribute to a competitive advantage through patents and high switching costs [3]. Financial Performance - As of March 6th, ABT's share price was $109.56, with trailing and forward P/E ratios of 29.45 and 19.30, respectively [1]. - The company has a strong balance sheet, featuring a debt-to-equity ratio of 30% and an interest coverage ratio of 75, alongside robust free cash flow generation [5]. - Abbott has maintained a dividend growth streak of 54 consecutive years, with a 5-year compound annual growth rate (CAGR) of 9.4% [5]. Market Challenges - Abbott faces several near-term challenges, including legal liabilities related to specialty infant formula, weakened demand post-price increases, declining COVID-testing revenues, and pricing pressures in China, contributing to a stock decline of approximately 15% this year [4]. - The dividend yield has approached 2.4% due to these pressures [4]. Long-term Outlook - Despite current headwinds, Abbott is well-positioned for long-term growth due to favorable trends in chronic disease management, an aging population, and emerging middle-class markets [5]. - The company's management, led by CEO Robert B. Ford, has a proven track record in navigating complex markets and executing acquisitions, such as the $21 billion Exact Sciences deal aimed at cancer diagnostics [4][5]. - For long-term investors, Abbott represents a compelling opportunity with a mix of defensive characteristics and innovation-driven growth potential [6].

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena partners presented clinical data updates for prasinezumab for Parkinson's and BMS-986446 for Alzheimer's disease at AD/PDâ"¢ 2026. ...

Core Viewpoint - Investors are facing significant market volatility, making it essential to consider companies that can perform well regardless of economic conditions, such as Bristol Myers Squibb, which offers a solid dividend stock opportunity [1]. Group 1: Company Overview - Bristol Myers Squibb is a leading player in the defensive pharmaceutical industry, known for its essential lifesaving drugs that maintain consistent demand through various economic conditions [2]. - The company's portfolio includes oncology, immunology, and rare diseases, although it has faced challenges due to patent cliffs, resulting in modest revenue growth [3]. Group 2: Financial Performance - In the fourth quarter, Bristol Myers reported sales of $12.5 billion, reflecting a year-over-year increase of only 1% [3]. - The growth portfolio, primarily consisting of therapies approved since 2019, generated $7.4 billion in sales during the fourth quarter, marking a 16% year-over-year increase [6]. Group 3: Dividend and Valuation - Bristol Myers offers a forward dividend yield of 4.2%, significantly higher than the S&P 500 average of 1.2%, and has increased its dividends by 65.8% over the past decade [6]. - The company's cash payout ratio stands at 39.3%, indicating potential for further dividend growth [6]. - Currently, Bristol Myers is trading at 9.5 times forward earnings, which is below the healthcare sector's average of 17.1 times [7].

Core Insights - Eli Lilly is well-positioned to attract future investments in India due to its strong scientific base, academic resources, and skilled workforce [1][10] - The company emphasizes the importance of regulatory data protection and a streamlined regulatory review process to enhance India's competitiveness in attracting high-value research [2][11] - Lilly's performance has been robust, driven by innovative medicines addressing significant unmet medical needs, with a positive outlook for future growth [7][8] Regulatory Environment - Regulatory data protection is crucial for the pharmaceutical industry, allowing companies to recoup investments made in clinical efficacy and safety data [2][5] - The regulatory review process in India involves three steps and can take up to one and a half years, which could be improved for faster approvals [2][11] - Harmonization with international guidelines for clinical trials is necessary to strengthen India's scientific capabilities and enable earlier access to innovative therapies [2][11] Market Dynamics - The affordability of medicines in India reflects the country's GDP per capita, ensuring that prices are significantly lower than in markets like Germany or the U.S. [6][11] - The innovative pharmaceutical industry is essential for the existence of generics, highlighting the interdependence between innovative and generic drug markets [5][11] Product Pipeline - Eli Lilly is expanding its product pipeline with significant developments in areas such as type 2 diabetes, obesity, Alzheimer's disease, and oncology [7][9] - The company plans to launch Donanemab for Alzheimer's in India by 2026, subject to regulatory approvals, and has an oral GLP-1 under review outside India [9][11] - Retatrutide, a triple agonist, has shown promising results with over 28% weight loss in studies, indicating strong potential in the obesity treatment market [9][11]

Eli Lilly has a R&D presence in India. What is the scale of Lilly's financial commitment to India going forward?India is well positioned to attract future investments. You look at the science, look at academia, look at the workforce, the talent, you know, I think you are super well positioned. Can it be improved further? Yes.I think there are also some additional things that could make India even more attractive for future investments. We saw some positive signs now with the announcement to increase accredi ...

Core Insights - New to The Street is a prominent financial media brand that broadcasts weekly on Bloomberg Television and Fox Business, reaching millions of households across the U.S., Latin America, and MENA regions [6] Group 1: Featured Companies - FreeCast (NASDAQ:CAST) is transforming digital media aggregation and streaming access for consumers worldwide [3] - KLED.ai is advancing AI-driven enterprise and data intelligence solutions [3] - Lantern Pharma (NASDAQ:LTRN) is a leader in AI-powered oncology drug development [3] - BlackBarn Restaurant is a premier culinary destination in New York City known for its farm-to-table excellence [3] - Virtuix (NASDAQ:VRTX) specializes in immersive virtual reality technology [4] - NRx Pharmaceuticals (NASDAQ:NRXP) focuses on advanced therapeutics for critical conditions [4] - PetVivo Holdings is involved in veterinary regenerative medicine [4] - DataVault AI (NASDAQ:DVLT) provides data monetization and tokenization infrastructure [4] - Roadzen (NASDAQ:RDZN) offers an AI-powered insurance and mobility platform [4] - Stardust Power (NASDAQ:SDST) is engaged in lithium and energy infrastructure solutions [4] - CISO Global (NASDAQ:CISO) is an enterprise cybersecurity leader [4] - The Sustainable Green Team (OTC:SGTM) focuses on climate and sustainable infrastructure solutions [4] Group 2: Media Reach and Impact - New to The Street has a combined platform reach exceeding 5.1 million subscribers, including 4.44 million on its YouTube channel and over 700,000 on the NewsOut Digital Network [4][5] - The platform utilizes various distribution channels, including LinkedIn, X, Instagram, and Facebook, along with iconic billboard placements in Times Square and NYC's Financial District [4] - New to The Street continues to outperform traditional financial media platforms in terms of reach, engagement, and measurable impact, establishing itself as a dominant force in next-generation financial media [5]

Core Viewpoint - Johnson & Johnson received FDA approval for ICOTYDE, an oral treatment for moderate to severe plaque psoriasis, which is seen as a positive development despite the stock's recent decline [1]. Group 1: Company Overview - Johnson & Johnson develops and sells healthcare products, including pharmaceuticals and medical technologies, with a focus on immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [2]. Group 2: Market Reaction - Despite the positive news regarding FDA approval, the stock finished down 0.35% in a challenging market session, indicating that broader market conditions may have overshadowed the company's announcement [1]. - The current market environment is described as a "terrible, horrible, no good, very bad day," suggesting that such conditions may create buying opportunities for investors in Johnson & Johnson [1].